Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
3.970 USD | -1.00% | +0.51% | +47.04% |
Nov. 13 | Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000 | MT |
Nov. 13 | VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Evolution of the average Target Price on VYNE Therapeutics Inc.
Price target over the last 5 years
History : Analyst Recommendations
71b4f09992339f0c524906b4cbc75.HA95K2HqjKEl3mvMKHjv_fw3tY163i8NHg4GDtWO8aA.eG4QTiraxZRp6ib1RgG-i6ZCxNw5jUJMUVZePr_ewcVXQh5RUZzkmG21Ig~61c4b7834a24a28fbbafc3478b9e097d
More recommendations
Analysts' Consensus
Sell
Buy

Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.970USD
Average target price
5.583USD
Spread / Average Target
+40.64%
High Price Target
6.000USD
Spread / Highest target
+51.13%
Low Price Target
5.000USD
Spread / Lowest Target
+25.94%
Consensus detail
Consensus revision (last 18 months)
Analysts covering VYNE Therapeutics Inc.
Cantor Fitzgerald | |
HC Wainwright | |
Northland Securities |
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
EPS Revisions
- Stock
- Equities
- Stock VYNE Therapeutics Inc. - Nasdaq
- Consensus VYNE Therapeutics Inc.